Get to know our clinical trials
Trial of ibrutinib with rituximab for the treatment of relapsed/refractory mantle cell lymphoma.
THE OBJECTIVE OF THIS STUDY IS TO DETERMINE THE RECOMMENDED DOSE OF IBRUTINIB WHEN ADMINISTERED TOGETHER WITH RITUXIMAB AND TO TEST WHETHER THIS COMBINATION IS SAFE AND EFFECTIVE IN TREATING MANTLE CELL LYMPHOMA THAT HAS RECURRED ("RELAPSED") OR WAS REFRACTORY TO PREVIOUS TREATMENT ("REFRACTORY").
Technical Summary
- Code EudraCT: 2022-000364-21
- Protocol number: 54179060MCL3004
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.